Skip to content

Ketamine: all studies

Page 72 of 449: studies 711 to 720 of 4,483, newest first. Back to the ketamine overview

Research

Long-Term Outcomes in Patients with Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study

The Journal of Clinical Psychiatry July 30, 2025 Balwinder Singh, Vanessa K. Pazdernik, Simon Kung et al.

Objective: This study examines the durability (defined as time between treatments) of intravenous ketamine (IV-KET) and intranasal esketamine (IN-ESKET) for treatment-resistant depression (TRD), in a real-world clinical setting with repeated ketamine/esketamine maintenance therapy. Methods: This was a single-center, observational study of adults with TRD who completed acute-phase treatment...

Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment

medRxiv July 29, 2025 Artemis Zavaliangos-Petropulu, Ginny Ghang, Toni Boltz et al. preprint

Background: Treatment-resistant depression (TRD) affects 30-50% of patients with major depressive disorder (MDD). Electroconvulsive therapy (ECT) and sub-anesthetic ketamine treatment can relieve TRD, yet their antidepressant mechanisms remain unclear. Peripheral blood gene expression offers a non-invasive proxy to examine potential treatment-response biomarkers. Methods: We conducted a...

DOI: 10.1101/2025.07.29.25332162 (opens in new tab) Full text (opens in new tab) Ketamine Electroconvulsive therapy Antidepressant Profiling computer programming +3

S-ketamine versus placebo for cortical spreading depolarisation in severe acute brain injury (KETA-BID): protocol for a pilot, randomised, blinded clinical trial.

BMJ Open July 28, 2025 Trine Hjorslev Andreasen, Markus Harboe Olsen, Christian Gluud et al. 2 citations

Cortical spreading depolarisation (SD) is a pathological wave of depolarisation in the cortex. SDs occur frequently after severe acute brain injury, and SDs in clusters can contribute to secondary brain damage in patients with severe acute brain injury through hypoperfusion and upregulation of cerebral metabolism in vulnerable brain tissue. Ketamine appears to inhibit SDs both in vitro and in...

DOI: 10.1136/bmjopen-2025-101426 (opens in new tab) Full text (opens in new tab) Anaesthesia in neurology Brain injuries Intensive care units Randomized controlled trial +1

Beyond Anesthesia: Ketamine’s Expanding Role in Chronic Pain and Psychiatric Disorders

Journal of Integrative Neuroscience July 25, 2025 Christopher Zaki 1 citation

OBJECTIVE: This review explores ketamine's expanding role in managing both chronic pain and mental health conditions, focusing on its pharmacologic mechanisms, clinical applications, and therapeutic potential. We assess its analgesic properties, FDA-approved application in the form of Spravato (esketamine) for depression, and off-label use for analgesia and psychiatric disorders. METHODS: A...

An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 25, 2025 Kiana Askariyan, Mohammad Taghi Joghataei, Samaneh Dehghan et al. 9 citations

The resurgence of psychedelic-assisted psychotherapy marks a pivotal evolution in mental health treatment, challenging traditional paradigms by integrating compounds such as psilocybin, LSD, MDMA, and ketamine into clinical practice. Historically marginalized due to regulatory and societal concerns, these agents are now gaining recognition for their unique neurobiological mechanisms and...

Sigma-1 Receptor Activation by Fluvoxamine Ameliorates ER Stress, Synaptic Dysfunction and Behavioral Deficits in a Ketamine Model of Schizophrenia.

Journal of Neuroimmune Pharmacology July 25, 2025 Mariam K Ahmed, Kareem Abdou, Weam W Ibrahim et al. 5 citations

Endoplasmic reticulum (ER) stress and misfolded proteins accumulation are recognized as central factors in the development of psychiatric disorders. This study evaluated the potential therapeutic effect of fluvoxamine, a potent sigma-1 receptor agonist in alleviating protein misfolding and the subsequent ER stress in ketamine-induced model of schizophrenia. NE100 hydrochloride, a sigma-1...

DOI: 10.1007/s11481-025-10231-4 (opens in new tab) Full text (opens in new tab) Chaperones Er stress Misfolded proteins Psychiatric disorders schizophrenia +4

High-frequency oscillations in the mammalian brain after ketamine and other NMDA receptor antagonists.

Journal of Psychopharmacology July 24, 2025 Mark Jeremy Hunt, Jacek Wróbel

Subanesthetic doses of ketamine produce complex neuropsychiatric effects, which include rapid psychotomimetic symptoms and antidepressant effects that can last several weeks. Despite over 60 years of research, the mechanism(s) of action underlying ketamine's effects in the brain remains largely mysterious. Neurophysiological field potential recordings provide a direct window into brain...

DOI: 10.1177/02698811251352454 (opens in new tab) Full text (opens in new tab) High-frequency oscillations Nasal respiration Networks Ketamine neuroscience ketamine +8

Self-reported changes and experiences with substance use among real-world patients treated with medical ketamine.

Experimental and Clinical Psychopharmacology July 24, 2025 Shahar Almog, Maribel Rodriguez Perez, Deepthi S Varma et al.

Ketamine is increasingly used in community clinics as a long-term treatment for different psychiatric and pain conditions, including substance use disorders. Data are lacking, however, regarding the potential influence of ketamine on other substance use. In this secondary analysis, we aimed to explore the relationship between medical ketamine and other substance use among real-world patients by...

DOI: 10.1037/pha0000788 (opens in new tab) Full text (opens in new tab) Ketamine therapy Medical ketamine Psychiatric ketamine Ketamine treatment +16

Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.

Nature Medicine July 24, 2025 Luke A. Jelen, David J Lythgoe, James Stone et al. 29 citations

We investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine administration in major depressive disorder. Twenty-six adults with major depressive disorder participated in a double-blind crossover study, receiving oral placebo or 50 mg naltrexone before an intravenous infusion of 0.5 mg per kg ketamine. Brain glutamatergic activity in the anterior...

DOI: 10.1038/s41591-025-03800-w (opens in new tab) Full text (opens in new tab) Ketamine Depression treatment Opioid system Mechanism of action

Pharmacokinetics, Safety, and Tolerability of (R)-Ketamine Hydrochloride Injection, a Novel Rapid-Acting Antidepressant, in Healthy Chinese Subjects.

Pharmaceuticals July 21, 2025 Rui Wang, Yuqian Yang, Tong Zhou et al.

Objectives: (R)-ketamine hydrochloride injection is a novel, rapid-acting antidepressant for the treatment of treatment-resistant depression. The aim of this study was to assess the pharmacokinetics, safety, and tolerability of (R)-ketamine hydrochloride injection in healthy Chinese subjects following ascending single intravenous doses ranging from 10.0 mg to 180 mg. Methods: This randomized,...